The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction.  In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]

Ischaemic left ventricular dysfunction is encountered frequently by physicians. Myocardial viability tests are utilised as a prospective tool that enables prediction of a patient’s recoverability. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the treatment paradigm for ischaemic left ventricular dysfunction and […]

Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]

Despite recent advancements in the treatment of pulmonary arterial hypertension (PAH), there are still several treatment gaps and unmet needs that exist. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany) to explore the need for more effective therapies that target multiple pathways involved in […]

Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine,  Hershey, PA, USA) to discuss purpose, […]

The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]

Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss the […]

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have displayed clinical significance reductions in the risk of heart failure hospitalizations. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss clinical trials using SGLT2is in patients with heart failure. Dr Borlaug presented an abstract entitled ‘Evaluation Of The Mechanism Of Benefit […]

Atrial Fibrillation Symposium 2023 gave an insight into new technologies for atrial fibrillation, atrial fibrillation ablation and left atrial appendage closure. In this touchCARDIO interview, we speak with Prof. Luigi Di Biase (Albert Einstein College of Medicine, Montefiore Health System, New York, NY, USA) to discuss his highlights from the Atrial Fibrillation Symposium, 2–4 February […]